Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of BL-M08D1 for Injection in Patients With Locally Advanced or Metastatic Solid Tumors

NCT06718621 is registered in ClinicalTrials.gov with Sichuan Baili Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT06718621
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06718621 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of BL-M08D1 for Injection in Patients With Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
February 12, 2025
Completion date
June 30, 2027
Enrollment
22 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor